Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

85.7%

-0.8% vs industry average

Late-Stage Pipeline

13%

1 trials in Phase 3/4

Results Transparency

17%

1 of 6 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A

3(60.0%)

Phase 2

1(20.0%)

Phase 3

1(20.0%)

5Total

N/A(3)

Phase 2(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT03648411Completed

Drug Resistance Among Asymptomatic Infection

Role: lead

NCT02758821Not ApplicableCompleted

The Impact of C-reactive Protein Testing

Role: collaborator

NCT02707653Not ApplicableCompleted

Sublingual Misoprostol for the Treatment of Incomplete Abortion: Operations Research

Role: collaborator

NCT03511443Not ApplicableUnknown

Evaluation of the Performance of a hsRDT Versus cRDT in Reactive Case Detection of Malaria Infections

Role: collaborator

NCT02792816Completed

Molecular Surveillance of Artemisinin Resistance Malaria in Myanmar

Role: lead

NCT02708199Completed

Molecular Assessment of Drug Resistance Markers in Asymptomatic Malaria Cases and Malaria Antibody Kinetic

Role: lead

NCT02461186Phase 2Withdrawn

Arterolane-PQP Versus DHA-PQP in Uncomplicated Falciparum Malaria in Eastern Myanmar

Role: collaborator

NCT01198574Phase 3Completed

Sub-clinical Inflammation and Iron Supplementation

Role: collaborator

All 8 trials loaded